Page results
-
London’s Business Design Centre opens its doors this week as a large- scale COVID-19 vaccination facility.
-
“Vaccines do not kill, the virus does”: that was the message from local leaders from a variety of different faiths during an event at the newly opened vaccination centre at the Business Design Centre in Islington.
-
Today, this National Day of Reflection, we remember those members of staff who we sadly lost due to COVID-19.
-
Dr Katherine Clesham is a consultant haematologist specialising in the treatment of teenagers and young adults with acute leukaemia and patients undergoing stem cell transplantation and CAR-T therapy.
-
The High Court has today (26 March) ruled that parents can consent on behalf of their child for hormone-blocking treatment in cases of gender dysphoria.
-
The spasticity team at The National Hospital for Neurology and Neurosurgery (NHNN) has produced a series of short animated videos. The films were funded by The National Brain Appeal, the charity dedicated to supporting NHNN.
-
A study of patients at UCLH and North Middlesex University Hospital published in The Lancet Infectious Diseases suggests that the B.1.17. variant of Covid-19 is not associated with more severe illness and death, but appears to lead to higher virus load.
-
UCLH-led research paper outlines mechanism behind rare cases of blood clots and low platelets after vaccination
-
UCLH is to lead an initiative to improve care for myeloma patients alongside Oxford University Hospitals NHS Foundation Trust (OUH) and University Hospital Southampton NHS Foundation Trust (UHS).
-
Prime Minister Boris Johnson visited the vaccination centre at the Islington Business Design Centre yesterday.
File results
-
FOI/2022/0550 - Patients that have been treated for glioblastoma brain cancer
-
FOI/2022/0553 - Patients tested for non-small cell lung cancer biomarkers
-
FOI/2022/0561 - Regulation (EU) 2016/425 Declarations of Conformity for all type IIR surgical masks provided as PPE to staff
-
FOI/2022/0571 - Treatment for biologic medicines in Dermatology
-
FOI/2022/0572 - Treatments for Hidradenitis Suppurativa and Psoriasis
-
FOI/2022/0573 - Use of WhatsApp by or within the Trust
-
FOI/2022/0513 - Myelofibrosis treatment
-
FOI/2022/0540 - Electronic patient record
-
FOI/2022/0541 - Serious Incidents Level 2 deaths/ serious harm
-
FOI/2022/0576 - Medications within dermatology